Posted by Michael Wonder on 16 May 2022
Spravato approved for reimbursement in Ireland for adults with treatment-resistant major depressive disorder
16 May 2022 - Janssen has announced that Spravato (esketamine) nasal spray has been granted reimbursement in Ireland for the treatment of adults living with treatment resistant major depressive disorder, in combination with a selective serotonin re-uptake inhibitor or serotonin and norepinephrine re-uptake inhibitor.
People are considered to have treatment resistant major depressive disorder, if they have not responded to at least two different treatments with antidepressants in the current moderate-to-severe depressive episode.
